Feature | April 05, 2011

Uterine Fibroid Embolization Improves Women's Lower Urinary Tract Symptoms

April 5, 2011 – Uterine fibroid embolization—an interventional radiology treatment for noncancerous growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids. The finding was announced by researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

"Uterine fibroid embolization or UFE continues to be an outstanding treatment choice for women with uterine fibroids, and—based on this study—this nonsurgical treatment improves related urinary tract problems," said James B. Spies, M.D., MPH, FSIR, professor and chair of the radiology department at Georgetown University Medical Center in Washington, D.C. "Fibroids can cause a variety of unpleasant, life-disrupting urinary symptoms for women, such as bladder frequency, urgency and the need to urinate during the night—and UFE can significantly improve these symptoms and daily life for women.”

He explained that uterine fibroids are the most frequent indication for hysterectomy in premenopausal women, and more than 300,000 women have this surgery performed annually in the United States to treat symptomatic uterine fibroids. "This research shows that minimally invasive uterine fibroid embolization effectively reduces fibroid-related urinary symptoms in women and should therefore be offered as a treatment choice,” Spies said. “Women need to know their options and make treatment choices that are right for them, knowing confidently that uterine fibroid embolization is an option to hysterectomy and myomectomy. Women who have uterine fibroids need to have a frank discussion about their treatment options with their gynecologists, urogynecologists, primary care providers and interventional radiologists to determine their best treatment option—especially if their urinary symptoms, such as urinary frequency and/or urgency, stress incontinence and urinary retention, are put in the background and not addressed initially.”

Uterine fibroids are benign tumors in the uterus that can cause prolonged, heavy menstrual bleeding that can be severe enough to cause anemia or require transfusion, disabling pelvic pain and pressure, urinary frequency, pain during intercourse, miscarriage and interference with fertility. Twenty to 40 percent of women age 35 and older have uterine fibroids of a significant size. African-American women are at a higher risk for fibroids: as many as 50 percent have fibroids of a significant size. Previous studies have already shown UFE, also referred to as uterine artery embolization or UAE, to be a safe and effective treatment compared to hysterectomy.

However, UFE offers less risk, less pain and a shorter recovery time compared to surgery, said Spies. It blocks tiny blood vessels that feed fibroids, causing the tumor to die and symptoms to subside. An interventional radiologist uses imaging to guide a thin catheter to the uterine artery and then releases tiny particles, the size of a grain of sand, into blood vessels feeding the fibroid, cutting off its blood flow and causing it to shrink and its symptoms to subside. UFE is a safe, effective, established treatment that has been widely available for years and is covered by insurance.

For the first time, researchers confirmed that uterine fibroid embolization does indeed control and relieve many lower urinary tract problems—such as urinary frequency and/or urgency and urinary retention—using standardized measures of urinary symptoms, said Spies. This prospective study included 46 women (average age of 44) with symptomatic fibroids who had lower urinary tract symptoms and underwent uterine fibroid embolization between March 2008 and May 2010. All subjects underwent a pre-procedure pelvic MRI and completed validated questionnaires that measured urinary distress and impact, pelvic organ/urinary incontinence/sex, uterine fibroid symptoms and quality of life. They also completed a standardized 48-hour bladder diary (preoperatively and three months after the treatment).

At three months after treatment, the women indicated an improvement in most urinary symptoms. Bladder diaries showed a significant reduction in the number of total voids at day and night. Uterine volume, dominant fibroid size, location or bladder compression did not affect the degree of improvement in urinary distress scores. However, researchers found no difference in incontinence episodes, stress incontinence or urge incontinence scores before and after the procedure.

For more information: www.SIRweb.org

Related Content

breast cancer, herceptin chemotherapy drug, heart damage, monitoring, Journal of Clinical Oncology study
News | Cardiac Diagnostics| April 28, 2016
April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
News | Interventional Radiology| April 25, 2016
The American Society of Radiologic Technologists (ASRT) has launched Vascular Interventional Essentials, a new...
women and men, heart disease symptoms, PROMISE trial, ACC.16
News | Cardiac Diagnostics| April 05, 2016
Chest pain and shortness of breath are the most common symptoms reported by both women and men with suspected heart...
women, heart disease risk, not informed, survey, ACC 2016
News | Womens Healthcare| April 01, 2016
Although nearly three-quarters of women taking a recent survey had one or more risk factors for heart disease, just 16...
American Heart Association, AHA, scientific statement, heart attacks, women, cardiovascular disease
News | Womens Healthcare| March 31, 2016
March 31, 2016 — After a lengthy review of increasing medical evidence, the American Heart Association has published
Toshiba, ACC 2016, American College of Cardiology, CT, MR, ultrasound, angiography, interventional radiology

Infinix 4-D CT image courtesy of Toshiba America Medical Systems.

News | Cardiac Imaging| March 30, 2016
Toshiba America Medical Systems Inc. announced it would demonstrate the following diagnostic imaging technologies at...
Artventive EOS embolization device, OCCLUDE post-market surveillance study, enrollment

Image courtesy of ArtVentive Medical Group Inc.

News | Embolization devices| February 24, 2016
ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Medtronic, CE Mark, IN.PACT Admiral DEB, arteriovenous AV access, hemodialysis, end-stage renal disease patients
News | Drug-Eluting Balloons| January 18, 2016
Medtronic plc announced that the IN.PACT Admiral drug eluting balloon (DEB) has received CE (Conformité Européene) Mark...
Overlay Init